CNTFRα Inhibitors
The chemical class of CNTFRα inhibitors consists of a diverse range of compounds that indirectly influence the activity of CNTFRα through modulation of various signaling pathways and cellular mechanisms. These inhibitors do not interact directly with CNTFRα; instead, they affect different biochemical pathways or cellular processes that are interconnected with the functioning of CNTFRα, leading to its inhibition.
Inhibitors such as H-89 and Staurosporine demonstrate the role of kinase inhibition in modulating signaling pathways that intersect with CNTFRα. By inhibiting protein kinases like PKA or a broad spectrum of kinases, these compounds can indirectly downregulate CNTFRα activity. Compounds targeting the PI3K/AKT pathway, such as LY294002 and Wortmannin, highlight another mechanism through which CNTFRα activity can be modulated. The inhibition of pathways like MEK/MAPK and mTOR by U0126, PD98059, and Rapamycin further illustrates the diverse targets within these chemical inhibitors. Additionally, the role of calcium signaling in CNTFRα regulation is underscored by the inclusion of calcium channel blockers like Nimodipine, Verapamil, and Nifedipine, and agents like Dantrolene that interfere with calcium release. These compounds indicate the importance of calcium-dependent pathways in the indirect regulation of CNTFRα.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a PKA inhibitor. By reducing PKA activity, it can indirectly downregulate signaling pathways that intersect with CNTFRα, potentially leading to its inhibition. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. It can indirectly inhibit CNTFRα by targeting kinases involved in pathways intersecting with CNTFRα signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By modulating the PI3K/AKT pathway, it can influence cellular processes that intersect with CNTFRα, leading to its indirect inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, similarly affects the PI3K/AKT pathway, potentially leading to indirect inhibition of CNTFRα. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, also a MEK inhibitor, can indirectly influence CNTFRα activity by altering the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can indirectly affect CNTFRα activity by altering downstream signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By impacting the p38 MAPK pathway, it can indirectly inhibit CNTFRα. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Nimodipine, a calcium channel blocker, can indirectly affect CNTFRα by altering calcium-dependent signaling pathways. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is another calcium channel blocker that can influence calcium signaling, potentially leading to the indirect inhibition of CNTFRα. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Similar to Nimodipine and Verapamil, Nifedipine can indirectly inhibit CNTFRα through its effects on calcium signaling. | ||||||